In diabetes, autophagy deficiency causes cardiomyopathy, and SGLT2 inhibitors are reported to mitigate the autophagy deficiency, resulting in cardioprotective effect (Aragon-Herrera et al., 2019; Zhang et al., 2020). This evidence concerns the gene SLC5A2 and diabetes mellitus.